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ABSTRACT
The CHL1 gene encodes a cell-adhesion molecule proposed as being a putative 
tumour-suppressor gene in breast cancer (BC). However, neither the underlying 
molecular mechanisms nor the clinical value of CHL1 downregulation in BC has 
been explored. The methylation status of three CpG sites in the CHL1 promoter 
was analysed by pyrosequencing in neoplastic biopsies from 142 patients with 
invasive BC and compared with that of non-neoplastic tissues. We found higher 
CHL1 methylation levels in breast tumours than in non-neoplastic tissues, either 
from mammoplasties or adjacent-to-tumour, which correlated with lower levels of 
protein expression in tumours measured by immunohistochemistry. A panel of five BC 
cell lines was treated with two epigenetic drugs, and restoration of CHL1 expression 
was observed, indicating in vitro dynamic epigenetic regulation. CHL1 was silenced 
by shRNA in immortalized but non-neoplastic mammary cells, and enhanced cell 
proliferation and migration, but not invasion, were found by real-time cell analysis. 
The prognostic value of CHL1 hypermethylation was assessed by the log-rank test 
and fitted in a Cox regression model. Importantly, CHL1 hypermethylation was very 
significantly associated with shorter progression-free survival in our BC patient series, 
independent of age and stage (p = 0.001). In conclusion, our results indicate that 
CHL1 is downregulated by hypermethylation and that this epigenetic alteration is an 
independent prognostic factor in BC.
INTRODUCTION
Breast cancer (BC) is the most common cancer 
among women and one of the leading causes of cancer-
related deaths worldwide [1–3]. It is a clinically 
heterogeneous disease, with at least five subtypes, 
according to the St Gallen International Expert Consensus 
in 2013 [4]: luminal A-like, luminal B-like/HER2-
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negative, luminal B-like/HER2-positive, HER2-positive 
(non-luminal) and triple-negative. Although BC incidence 
remains high, an increase in overall survival (OS) has 
been attributed to advances in early detection programmes 
and therapeutic approaches directed against molecular 
biomarkers, such as hormone receptors and HER2, which 
are overexpressed and amplified in luminal and HER2 
subtypes, respectively. From the therapeutic point of 
view, their cell-signalling transduction abilities have been 
successfully abolished by administration of tamoxifen 
and trastuzumab, respectively [5–7]. Nevertheless, BC 
prognosis is quite variable and approximately 20-30% of 
early-stage cases will eventually experience recurrence 
and develop distant metastasis. Currently, however, there 
is no acceptable method for monitoring patients who 
are likely to progress [8]. BC is thought to result from 
the presence of certain abnormal genetic and epigenetic 
changes in tumour suppressor genes, such as TP53 or 
BRCA1, and proto-oncogenes, like members of the PI3K 
signalling pathway, among others [4, 9]. A thorough 
understanding of the mechanisms responsible for BC 
development and progression is still needed to identify 
prognostic biomarkers.
Gene expression-based approaches have added 
significant prognostic and predictive value to pathological 
staging, histological grade and standard molecular 
marker identification [10]. However, the high cost of 
expression profiling and the molecular instability of 
mRNA have limited its clinical use, so expression-based 
BC classification has not become a routine method 
[11]. In fact, the most recent consensus [4] agreed a 
BC classification based on the expression of various 
immunohistochemical markers (presence or absence 
of oestrogen, progesterone and HER2 receptors and 
Ki67). Thus, although distinguishing BC subtypes by 
immunohistochemical markers is considered the gold 
standard, there is an urgent need to identify new and well-
defined prognostic biomarkers to stratify BC patients with 
good and poor prognosis [12].
Epigenetic alterations are common molecular 
abnormalities in cancer, including DNA methylation, 
alterations in microRNA profiling and post-translational 
modifications of histones [13]. Over the past decade, 
aberrant DNA methylation has been recognised as one of 
the most common molecular abnormalities in BC [14, 15]. 
Methylation of certain genes has been related to clinical 
and pathological characteristics of breast tumours, and 
is considered a biomarker of diagnosis [16], hormone 
receptor [17] and HER2 [18] status, response to tamoxifen 
[17] and chemotherapy [19], metastases during follow-
up [14], and has demonstrated its value as a predictor of 
survival [17, 20].
The CHL1 gene (Close Homolog of L1, also 
known as L1CAM2, Entrez Gene accession number 
10752) encodes a member of the L1 family of neural cell 
adhesion molecules essential for the brain development 
and involved in signal transduction pathways. Some of 
these proteins, such as L1CAM, are expressed in a wide 
range of tissues in addition to the brain, and are known to 
play an important role in carcinogenesis and progression 
in a variety of human cancers by overexpression and 
association with poor prognosis [2, 21]. Interestingly, 
L1CAM upregulation promotes cell adhesion and 
migration and is associated with shorter progression-free 
survival (PFS) and overall survival (OS) in BC [22–24].
However, very few studies have focused on the role 
of CHL1 in cancer [2, 21]. There is weak evidence that 
CHL1 expression is downregulated at the mRNA level in 
BC tissues relative to non-cancerous breast tissues [21], 
but nothing is known about the causes of this silencing. 
The biological role of CHL1 in BC has been reported in 
only a single study, in which, in addition to confirming 
CHL1 downregulation at the mRNA and protein levels 
in BC tissues and cell lines, the authors found that 
overexpression of CHL1 impaired cell proliferation and 
invasion, while CHL1 depletion caused the opposite 
effect in vitro, and promoted tumour formation in vivo 
[2]. Nevertheless, the clinical value of CHL1 silencing 
in human tissues as a potential biomarker of prognosis 
remains to be elucidated. The aim of this study was to 
determine the mechanisms and clinical implications of 
CHL1 downregulation in BC.
RESULTS
CHL1 hypermethylation is present in BC
To determine the methylation status of the CHL1 
gene, three CpG sites in its promoter were pyrosequenced 
in a series of 142 breast tumours, 45 paired tumour and 
adjacent-to-tumour tissues, and 19 non-neoplastic breast 
tissues from reduction mammoplasties (Supplementary 
Figure 1). Since pyrosequencing provides a quantitative 
measure of methylation, the optimal cut-off value 
distinguishing statistically between the unmethylated 
and methylated status of each of the CpG sites was 
estimated by ROC curve analysis: 17.5% methylation 
for CpG1, 4.5% methylation for CpG2, and 9.5% for 
CpG3 (Table 1). We also considered that a case had 
hypermethylated CHL1 when the three tested CpG sites 
simultaneously showed methylation percentages above 
their cut-off values. In contrast, non-neoplastic breast 
samples displayed very low percentages of methylation 
(< 11%) (Figure 1). Importantly, non-neoplastic 
adjacent-to-tumour tissues harboured significantly lower 
methylation levels in all CpG sites than tumour tissues, 
but slightly higher levels than those of non-neoplastic 
tissues (Figure 1). Interestingly, this epigenetic alteration 
was maintained across all BC subtypes (Supplementary 
Figure 2).
These results indicate, for the first time, that a 
subset of breast tumours has higher levels of CHL1 gene 
methylation than do adjacent-to-tumour tissues and non-
neoplastic samples.
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CHL1 protein expression pattern in mammary 
tissues
Since DNA methylation is a well-known mechanism 
of gene expression regulation, the expression pattern of the 
CHL1 protein was measured by immunohistochemistry in 
57 BC tissues, their adjacent-to-tumour counterparts and 
20 non-neoplastic tissues from reduction mammoplasties. 
We found a significantly higher level of expression in 
both types of non-neoplastic cells relative to tumour cells, 
being slightly lower in adjacent-to-tumour than in non-
neoplastic tissue (Figure 2 and Supplementary Figure 3A). 
Although the predicted location of CHL1 protein is the 
cell membrane, the pattern of expression was cytoplasmic 
without nuclear or membrane expression (Supplementary 
Figure 3B), even when using two different antibodies 
(data not shown). Furthermore, the same cytoplasmic 
pattern with a lack of membrane staining was observed 
by immunofluorescence in CHL1-expressing immortalized 
but non-neoplastic mammary cells (Supplementary Figure 
3C).
These results are consistent with the epigenetic 
pattern we observed: breast tumours, with higher 
methylation levels, displayed a lower level of protein 
expression than did non-neoplastic tissues.
CHL1 expression can be modulated by 
epigenetic drugs in BC cell lines
The methylation status of the CpG1 site in the CHL1 
gene promoter that had been examined by pyrosequencing 
in BC samples was analysed in a panel of four BC cell 
lines and one immortalized but non-neoplastic mammary 
cell line. We found that the majority of BC cell lines had 
higher levels of methylation overall than non-neoplastic 
HBL-100 cells. Accordingly, mRNA levels of CHL1 
were lower in BC cell lines than in non-neoplastic HBL-
100 cells, as assessed by qRT-PCR. In fact, we observed 
a strong and significant correlation between CHL1 
methylation and expression (Spearman’s correlation 
coefficient = - 0.9; p = 0.037) (Figure 3A), suggesting that 
CHL1 expression may also be regulated by methylation 
in vitro in BC.
In order to test whether CHL1 expression can be 
modulated by epigenetic mechanisms, all cell lines were 
treated with two epigenetic drugs. We found by qRT-PCR 
that AZA+TSA treatment restored CHL1 expression in all 
BC cell lines (Figure 3B), while single treatment was not 
as effective as the drug combination (data not shown).
These results indicate that the hypermethylation 
contributes to the regulation of CHL1 expression in BC, 
and that it can be dynamically modulated by in vitro 
epigenetic treatments.
CHL1 silencing promotes cell proliferation and 
migration of non-neoplastic mammary cells
To determine the effect of CHL1 silencing in BC, 
we inhibited CHL1 expression in the only mammary 
tissue-derived cell line expressing high levels of CHL1: 
the immortalized but non-neoplastic HBL-100 cell line. 
To this end, we inserted two shRNAs against CHL1 and 
one scramble shRNA into the pHIV1-SIREN-PuroR 
plasmid, and lentiviruses were produced upon transfection 
in 293T cells. HBL-100 cells were then transduced and 
selected with puromycin. Western blot showed that the 
shCHL1_1 was more efficient at depleting CHL1 protein 
than shCHL1_2 (Figure 4A). Concomitantly, shCHL1_1, 
but not shCHL1_2, significantly enhanced HBL-100 cell 
proliferation (Figure 4B) and migration (Figure 4C), but 
not invasion (Figure 4D).
These observations indicate that CHL1 silencing 
could be important for in vitro breast tumour cell growth.
CHL1 hypermethylation predicts BC 
progression
Finally, we aimed to examine the clinical value of 
CHL1 hypermethylation in our series of 142 BC patients 
(Supplementary Table 1). Using the cut-off values of 
Table 1: Methylation status of CHL1 in breast samples
 CpG1 CpG2 CpG3 All CpGs
Median % methylation in breast tumours 
(range)
18
(0-69)
5
(0-96)
5
(0-96)
 
Median % methylation in adjacent-to-
tumour tissues (range)
6
(0-22)
1
(0-17)
1
(0-15)
 
Median % methylation in non-neoplastic 
breast samples (range)
5
(0-11)
0
(0-22)
0
(0-20)  
Cut-off value (related to PFS) 17.5 4.5 9.5
Above cut-off in 
all CpGs
PFS: progression-free survival.
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CHL1 methylation mentioned above, we found that the 
methylation status of the CHL1 gene was very significantly 
associated with shorter PFS (p < 0.001) (Figure 5), but 
not with OS (data not shown). We confirmed in our 
series that other well-known prognostic factors, such as 
lymph node involvement, histological grade and stage, 
substantially contributed to a shorter PFS (Supplementary 
Figure 4). Therefore, the independent impact of CHL1 
hypermethylation on progression, regardless of those 
important clinical variables, was tested in a Cox regression 
model. Importantly, we found that methylation in all the 
studied CpG sites in the CHL1 promoter was still very 
significantly associated with poor PFS (p = 0.001), 
irrespective of age and stage (Table 2). The other clinical 
Figure 1: Epigenetic status of CHL1 in BC patients. The methylation of three CpG sites in the CHL1 gene promoter was interrogated 
by pyrosequencing in a series of 142 BC cases, 45 adjacent-to-tumour tissues, and 19 non-neoplastic mammary tissues from reduction 
mammoplasties. The horizontal lines in each group represent the median of the series. (***, p < 0.001).
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Figure 2: CHL1 protein expression in BC. Immunohistochemistry was employed to measure CHL1 expression in 57 paired breast 
tumour and adjacent-to-tumour samples, along with 20 non-neoplastic tissues from reduction mammoplasties. It was scored as: 0, no 
expression; 1: weak expression; 2: intermediate expression; and 3: strong expression (***, p < 0.001; *, p < 0.05). Images were acquired at 
400x magnification using a Leica DMD 108 digital microscope (Leica, Wetzlar, Germany).
Figure 3: Molecular status of CHL1 in BC cell lines. A. Correlation between CHL1 hypermethylation in the CpG1 site and 
expression in BC cell lines (Spearman’s correlation coefficient = -0.9; p = 0.037), measured by pyrosequencing and qRT-PCR, respectively. 
U-87 MG cells were used as a positive control for CHL1 expression, but were not included in the correlation analysis (RQ, relative 
quantification). B. Restoration of CHL1 expression in BC cell lines by treatment with 4 μM 5-aza-dC for 72 h and 300 nM TSA for 24 h 
(AZA+TSA), measured by qRT-PCR.
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parameters significantly correlated with PFS (histological 
grade and lymph node involvement) were not included in 
the Cox regression model due to their association with the 
stage (p < 0.001). We also observed that the methylated 
status of all tested CpG sites of CHL1 promoter displayed 
a hazard ratio of 5 (Table 2).
These results suggest that CHL1 hypermethylation is 
of independent value as a predictor of shorter PFS in BC.
DISCUSSION
The CHL1 gene has been described as being 
downregulated in BC tissues with biological effects on 
cell proliferation in both in vitro and in vivo BC models 
[2, 21]. However, the mechanisms underlying CHL1 
silencing and its potential clinical role have not previously 
been explored. This gene is located on the short arm of 
chromosome 3 (band 3p26), a commonly deleted region 
in malignant peripheral nerve sheath tumours [25], 
nasopharyngeal carcinomas [26] and oral squamous 
cell carcinomas, in which the loss of this region is of 
prognostic value [27]. In BC, besides being deleted, this 
region has also been reported to harbour candidate tumour 
suppressor genes [21]. Deletions in one allele are usually 
accompanied by hypermethylation of the other [28]. In 
this study, we show for the first time that the CHL1 gene, 
located in this region, is silenced in a subset of invasive 
BC cases due to promoter hypermethylation, but not in 
adjacent-to-tumour tissue and non-neoplastic tissue from 
mammoplasties. This epigenetic alteration has been found 
by pyrosequencing, a technique that yields quantitative 
measurements of methylation in contrast to methylation-
specific PCR [29–33]. Consistent with the observed 
hypermethylation, we have found that tumour cells in BC 
tissues have a lower level of CHL1 expression compared 
with non-neoplastic adjacent-to-tumour cells. Importantly, 
Figure 4: Effects of CHL1 silencing on immortalized but non-neoplastic mammary cells. A. HBL-100 cells were transduced 
with pHIV1-SIREN+scramble, pHIV1-SIREN+shCHL1_1, or pHIV1-SIREN+shCHL1_2 and selected with puromycin for 11 days. CHL1 
silencing efficiency was checked by western blot, using α-tubulin as a loading control. Numbers indicate the amount of CHL1 relative to 
that of α-tubulin, as measured by densitometry. B. Cell proliferation was measured by RTCA for 5 additional days upon CHL1 silencing. 
C. Effects of CHL1 knockdown on cell migration were measured for 24 h. Images were acquired at 50x magnification with NIS-Elements, 
using an Olympus BX51 microscope (Olympus, Tokyo, Japan). D. Cell invasion was measured by RTCA for 3 additional days after CHL1 
silencing.
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this is the first report of the immunohistochemical pattern 
of CHL1 expression in invasive BC.
The biological role of CHL1 silencing in BC was 
analysed in the only mammary tissue-derived cell line 
expressing high levels of CHL1 mRNA available to 
us: an immortalized but non-neoplastic mammary cell 
line, HBL-100. All BC cell lines displayed very low 
CHL1 expression, as previously described [2]. We also 
demonstrated that CHL1 hypermethylation can be reversed 
by epigenetic treatment, since demethylating agents and 
histone deacetylase inhibitors modulated dynamics of 
CHL1 expression in vitro and restored its silenced status 
in BC-derived cell lines. By reducing CHL1 protein 
levels with shRNA, a dramatic increase in non-neoplastic 
HBL-100 cell proliferation and migration was found 
(around 2-fold), but not in cell invasion, suggesting that 
CHL1 might act as a tumour suppressor gene in the early 
stages of BC development. Interestingly, the expression 
of L1CAM, another neural cell adhesion molecule 
from the same family as CHL1, has been described to 
promote BC cell adhesion and migration in vitro, while 
cell invasion was also unaffected [24]. Our results are 
consistent with the only study to date to demonstrate 
the biological role of CHL1 in BC [2], in which tumour 
cell proliferation and invasion were suppressed and 
stimulated by overexpression and depletion of CHL1, 
respectively, due to its interaction with the cytoskeleton 
[22]. The new in vitro finding observed in our study is 
that CHL1 knockdown can also affect non-neoplastic cell 
proliferation, other than tumour cell spreading, as reported 
by He et al [2]. It has been proposed that during initial 
growth, CHL1 is silenced in tumour cells to facilitate in 
situ tumour growth, acting as a tumour suppressor gene; 
CHL1 is then re-expressed on the edge of the tumour mass 
and around tumour vessels to promote migration and local 
invasive growth, and acts as an oncogene to initiate the 
metastatic process [21].
Figure 5: Prognostic value of CHL1 hypermethylation in a series of 142 BC patients. (A) Association between shorter 
periods of progression-free survival and CHL1 hypermethylation in each of the three CpG sites analysed, and in all of them simultaneously. 
Cut-off values for hypermethylation were calculated by ROC analysis: 17.5% for CpG1; 4.5% for CpG2; 9.5% for CpG3.
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The clinical role of CHL1 hypermethylation in 
invasive BC has also been studied here for the first time. 
In this context, a cut-off value of CHL1 hypermethylation 
has been established to stratify unmethylated and 
methylated cases, as seen with MGMT hypermethylation, 
which has been useful for predicting both PFS and 
OS in glioblastoma [34]. Importantly, we observed 
that CHL1 hypermethylation was very significantly 
associated with shorter PFS in our large series of BC 
patients. Accordingly, an association between low CHL1 
mRNA levels and unfavourable histological grade was 
previously reported in a small series of breast tumours 
[2]. Most importantly, CHL1 hypermethylation was 
an independent prognostic factor in our series that 
predicted shorter PFS, regardless of other crucial factors 
in BC prognosis, such as age or stage. Thus, testing 
CHL1 hypermethylation by pyrosequencing, an easy-
to-implement technique that returns an achievable and 
quantitative measurement [35], could have a significant 
clinical impact in BC patients.
In conclusion, our results show for the first time that 
CHL1 promoter is hypermethylated in BC and that this 
epigenetic alteration, established with a quantitative cut-
off value by pyrosequencing, is an independent prognostic 
biomarker in invasive BC.
MATERIALS AND METHODS
Patient samples
We analysed a series of 142 formalin-fixed, 
paraffin-embedded samples from BC patients alongside 
20 non-neoplastic mammary samples from reduction 
mammoplasties. Paired adjacent-to-tumour tissue was 
available in 57 cases. All patients were diagnosed with 
primary invasive breast cancer between 1996 and 2006 in 
the Pathology Department of the Complejo Hospitalario 
de Navarra (Navarra Public Health System, Pamplona, 
Spain). Pathological and clinical characteristics are 
summarised in Supplementary Table 1. All tumours were 
surgically removed and staged according to their size, 
histological grade and lymph node involvement, and 
diagnosis was reclassified using the recommended criteria 
of the St Gallen International Expert Consensus in 2013 
[4], considering a Ki-67 threshold of 14% [36], and upon 
microscopic evaluation by two independent observers 
with expertise in breast pathology. It was ensured that all 
cases harboured at least 70% tumour cells. None of the 
patients had received radiotherapy or chemotherapy before 
surgery. The study was approved by the Regional Clinical 
Research Ethics Committee and samples were obtained in 
accordance with the current Spanish legislation regarding 
written informed consent.
Cell lines and treatments
A panel of four human BC cell lines was used in 
this study: T-47D (luminal-like) and BT-549 (triple-
negative) were purchased from the American Type 
Cell Collection (ATCC, Rockville, MD, USA); HCC-
1937 and MDA-MB-468 (all from the triple-negative 
subtype) were obtained from the Leibniz Institute 
DSMZ - German Collection of Microorganisms and Cell 
Cultures (Braunschweig, Germany). Additionally, one 
immortalized but non-tumorigenic human mammary 
epithelial cell line (HBL-100) was obtained from the 
ATCC (Rockville, MD, USA). Two cell lines derived 
from other tissues were used (all from ATCC, Rockville, 
MD, USA): human embryonic kidney 293T cells, which 
were used for transfection experiments; and U-87 MG, 
derived from human malignant glioma, which was 
used as a positive control for CHL1 expression. All 
these cell lines were grown in RPMI-1640 or DMEM, 
supplemented with 10% foetal bovine serum and 1% 
penicillin/streptomycin (all from Life Technologies, 
Carlsbad, CA, USA), at 37°C in a humidified atmosphere 
with 5% CO2.
All cell lines at low passage were treated with the 
demethylating agent 5-aza-2′-deoxycytidine (AZA) and 
the histone deacetylase inhibitor trichostatin A (TSA) 
(both from Sigma-Aldrich, St Louis, MO, USA). Briefly, 
cells were seeded at a density of 1x105 cells/ml, allowed 
to attach overnight, and treated with 4 μM AZA for 72 h 
added freshly every 24 h, 300 nM TSA for 24 h, or the 
combination of the two drugs for the last 24 h, using PBS 
as a vehicle control.
Table 2: CHL1 hypermethylation as an independent prognostic factor
Variable Hazard ratio (95% CI) p-value
Age 1.012
(0.970 – 1.055)
0.586
Stage 2.406
(0.801 – 7.233)
0.118
CHL1 hypermethylation – all CpGs 5.061
(1.864 – 13.739)
0.001
Cox regression model shows the independent effect of each prognostic factor on progression-free survival (CI, confidence 
interval).
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DNA extraction, bisulphite conversion and 
pyrosequencing
To determine the methylation status of the CHL1 
gene, DNA was extracted from formalin-fixed, paraffin-
embedded breast tumours, non-neoplastic mammary 
tissues and BC cell lines using a QIAamp DNA FFPE 
Tissue kit (Qiagen, Hilden, Germany). Bisulphite 
conversion of DNA was performed to transform non-
methyl cytosines into thymidines, while methyl cytosines 
remained intact. 500 ng of DNA were treated with freshly 
prepared bisulphite using an EZ DNA Methylation-Gold 
kit (Zymo Research, Irvine, CA, USA), following the 
manufacturer’s instructions. Pyrosequencing was carried 
out to analyse the methylation of three CpG sites in the 
promoter of the CHL1 gene (Supplementary Figure 1). For 
this purpose, first, PCR amplification was performed using 
Immolase DNA polymerase (BioLine, London, UK) in a 
final volume of 30 μl containing 2 μl of bisulphite modified 
DNA and the primers indicated in Supplementary Table 2. 
Amplification conditions were: initial DNA polymerase 
activation at 95°C for 10 min, followed by 50 cycles at 
95°C for 30 s, 58–60°C for 30 s and 72°C for 30 s, and 
a final extension at 72°C for 7 min. The amplicons were 
resolved by electrophoresis using 2% (w/v) agarose gel in 
1x Tris-borate-EDTA buffer, stained using SYBR Red Safe 
(Life Technologies, Carlsbad, CA, USA) and visualized 
in a standard transilluminator (ChemiDoc XRS, Bio-Rad 
Laboratories, Hercules, CA, USA). DNA methylation 
analysis was quantified as follows: 20 μl of PCR 
products were immobilized with Streptavidin Sepharose 
HP Beads (GE Healthcare Bio-Sciences, Pittsburgh, 
PA, USA) using a Vacuum Prep Workstation. This was 
followed by annealing (80°C for 2 min) the sequencing 
primers (Supplementary Table 2) and pyrosequencing 
in a PyroMark Q24 using PyroMark Gold Q24 reagents 
and PyroQ-CpGTM Software (v.1.0.11) (all from Qiagen, 
Hilden, Germany). Results were analysed using PyroMark 
Q24 software in CpG analysis mode.
Immunohistochemistry
3-μm sections of 57 BC tumours and their matched 
adjacent-to-tumour counterparts, along with 20 non-
neoplastic tissues from reduction mammoplasties, were 
placed on slides and then deparaffinized, hydrated and 
treated to block endogenous peroxidase activity. After 
incubating with the primary rabbit polyclonal CHL1 
antibody (ab106269, Abcam, Cambridge, UK) at 1:800 
dilution for 20 min (antigen retrieval at 90°C for 20 min, 
pH = 6.0), the antibody was developed using a Bond 
Polymer Refine Detection kit (Leica, Wetzlar, Germany) 
and visualized with diaminobenzidine. The pattern of 
expression was evaluated blind by two independent 
observers. The intensity of expression was ascribed to one 
of four categories: 0, no expression; 1, weak expression; 
2, intermediate expression; 3, strong expression. Images 
were acquired with a Leica DMD 108 digital microscope 
(Leica, Wetzlar, Germany).
Immunofluorescence
In order to explore the CHL1 expression pattern 
in cultured cells, the immortalized but non-neoplastic 
mammary HBL-100 cells were seeded on coverslips and 
allowed to attach overnight. Then, cells were fixed with 
4% paraformaldehyde, blocked with 5% foetal bovine 
serum in PBS at room temperature for 1 h, and incubated 
with anti-CHL1 primary antibody (ab106269, Abcam, 
Cambridge, UK) at 4°C overnight at 1:800 dilution, 
and with AlexaFluor 488 secondary anti-rabbit (1:200) 
and AlexaFluor 594 Phalloidin (1:500) (both from Life 
Technologies, Carlsbad, CA, USA) at room temperature 
for 1 h. Finally, samples were mounted on slides with 
DAPI to counterstain nuclei. Confocal microscopy 
was performed with a Leica TCS SP5 laser scanning 
microscope (AOBS) (Leica, Wetzlar, Germany) using 
excitation wavelengths of 488 nm (for FITC) and 561 nm 
(for Texas Red).
RNA extraction and quantitative reverse 
transcription PCR (qRT-PCR)
qRT-PCR was performed to measure the levels of 
CHL1 expression in BC-derived cell lines and to check the 
restoration of gene expression by AZA+TSA treatment. 
To this end, first, total RNA was extracted and purified 
using an RNeasy Mini Kit (Qiagen, Hilden, Germany) 
following the manufacturer’s instructions. 500 ng of total 
RNA were retrotranscribed using a PrimeScript™ RT 
Reagent Kit (TaKaRa, Otsu, Japan) at 37°C for 15 min 
and 85°C for 5 s. 1 μl of the resulting cDNA was placed 
in a 96-well plate with 0.5 μl TaqMan probes (CHL1: 
Hs00544069_m1 from Life Technologies, Carlsbad, CA, 
USA; and GAPDH: Hs.PT.39a.22214836, from IDT, 
Coralville, Iowa, USA) and 19 μl of mix were included 
in the Premix Ex Taq™ kit (TaKaRa, Otsu, Japan). PCR 
amplification was performed in triplicate using the Quant 
Studio 12K Flex (Life Technologies, Carlsbad, CA, USA) 
under thermal cycler conditions of 95°C for 30 s and 40 
cycles at 95°C for 5 sec and 60°C for 34 s. The cycle 
threshold (Ct) values were calculated using Quant Studio 
software (Life Technologies, Carlsbad, CA, USA), and 
the relative quantification (RQ) was calculated by the ΔCt 
method (RQ = 2−ΔCt), using GAPDH as the endogenous 
control gene.
CHL1 silencing in immortalized but non-
neoplastic mammary cells
To study the functional role of CHL1 in BC, HBL-
100 cells were transduced using lentivirus containing 
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short-hairpin RNAs (shRNAs) against CHL1. For 
their construction, two sequences targeting CHL1 
(shCHL1_1: 5’-GCAGCAATATTAGCGAGTATAT-3’ and 
shCHL1_2: 5’-GCGTCCATTGATACAAACCAAA-3’) 
and one scramble sequence 
(5’-GCAACAAGATGAAGAGCACCAA-3’) were 
inserted into the pHIV1-SIREN-PuroR plasmid [37] 
through digestion with BamHI and EcoRI restriction 
enzymes (Life Technologies, Carlsbad, CA, USA) 
and ligation with the T4 DNA ligase enzyme (New 
England Biolabs, Ipswich, MA, USA). Plasmids were 
purified using the Qiagen Plasmid Midi kit (Qiagen, 
Hilden, Germany) and sequenced to check the ligation. 
Lentiviruses containing the scramble, shCHL1_1 
or shCHL1_2 were produced by the three-plasmid 
cotransfection method in 293T cells: p8.91, encoding 
HIV-1 structural proteins; pVSVg, encoding the vesicular 
stomatitis virus surface glycoprotein; and the constructed 
plasmids (scramble, shCHL1_1 or shCHL1_2). Media 
containing viruses were recovered and filtered every 
day for a week, ultracentrifuged at 25,000 rpm at 4°C 
for 2 h and stored at -80°C until used. Since the plasmid 
contains the puromycin resistance gene for mammalian 
cell selection, sensitivity to this antibiotic was first tested 
in HBL-100 cells, and an optimal concentration of 1 μg/
ml was chosen from a wide range of possibilities. HBL-
100 cells were then transduced with 5 μl of each lentivirus 
for 24 h (multiplicity of infection: 2.5 lentiviral particles/
cell), and once the lentiviral particles had been removed, 
puromycin was added to the culture medium and cells 
were maintained for 2 weeks for selection.
Western blot
CHL1 silencing efficiency was checked by western 
blot. Upon puromycin selection, cells transduced with the 
scramble, shCHL1_1 or shCHL1_2 were harvested, lysed 
with 30 μl of RIPA buffer (Sigma-Aldrich, St Louis, MO, 
USA) containing a cocktail of protease inhibitors (Roche, 
Basel, Switzerland). After centrifugation at 8000 x g for 
10 min at 4°C, proteins contained in the supernatants 
were quantified using the Protein DC kit (Bio-Rad, 
Hercules, CA, USA) in an Epoch plate reader (BioTek, 
Winooski, VT, USA) and following manufacturer’s 
recommendations. For western blot, 80 μg of proteins 
were resolved by SDS-PAGE in a 10% gel and transferred 
to a nitrocellulose membrane (Bio-Rad, Hercules, CA, 
USA). The membrane was blocked with 5% non-fat milk 
and incubated with the anti-CHL1 antibody (ab106269, 
Abcam, Cambridge, UK) at a 1:500 dilution, overnight 
and at 4°C. It was then incubated with the secondary anti-
rabbit antibody (Bio-Rad, Hercules, CA, USA) at 1:3000 
for 1 h at room temperature. The signal was detected 
with the SuperSignal West Pico Chemiluminiscent 
Substrate kit (Thermo Scientific, Rockford, IL, USA) in 
a ChemiDoc (Bio-Rad, Hercules, CA, USA) using the 
ImageLab software. The α-tubulin antibody (T-6074 from 
Sigma-Aldrich, St Louis, MO, USA) and the secondary 
anti-mouse antibody were used at 1:10000 and 1:2000, 
respectively, for 30 min, as a loading control. Finally, 
the intensity of bands was quantitated by densitometric 
analysis using ImageJ software.
Real-time cell analysis (RTCA) of cell 
proliferation and invasion
To evaluate the functional role of CHL1 in cell 
proliferation, HBL-100 cells transduced with scramble 
and two shCHL1 were seeded (1x104 cells/well) into 
400 μl of medium in an E-plate L8 device (iCELLigence 
system, ACEA Biosciences, San Diego, CA, USA), after 
measuring the background in 100 μl of medium. The 
invasion assays were performed in CIM-16 plates with 
8-μm-pore membranes (ACEA Biosciences, San Diego, 
CA, USA). Wells were coated with 30 μl of 5% Matrigel 
(BD Biosciences, San Jose, CA, USA) and allowed to gel 
at 37°C and 5% CO2 for 4 h. Then, the lower chamber 
wells were filled with 160 μl of medium containing 10% 
foetal bovine serum and the top chamber wells with 40 μl 
of serum-free medium. The two portions were assembled 
together and allowed to equilibrate for 1 h at 37°C and 5% 
CO2. Cells were incubated for 16 h in 0.05% foetal bovine 
serum media; for seeding, the cells were rinsed with PBS, 
trypsinized and resuspended in serum-free medium. A total 
of 4 × 104 cells/well were seeded onto the top chamber of 
CIM-16 plates and placed into the xCELLigence system 
(ACEA Biosciences, San Diego, CA, USA) for data 
collection after background measurement.
Two replicates for each condition were analysed. 
Cell attachment, spreading, proliferation and invasion 
were monitored by RTCA for 3-5 days, on the basis of 
changes in cell-sensor impedance, as previously described 
[33, 38].
Cell migration
To examine the role of CHL1 silencing on cell 
migration, HBL-100 cells transduced with the scramble, 
shCHL1_1 and shCHL1_2 were seeded into 6-well plates 
at a density of 2x105 cells/well. When they had nearly 
reached confluency, cells were serum-starved for 8 h, then 
three scratches were made in the cell monolayer with a 10-
μl pipette tip, and cells were washed twice with PBS 1X. 
Some cells were harvested here (time, 0 h), while others 
were maintained for 24 h in a culture medium containing 
5% foetal bovine serum, as previously described [22]. 
Finally, harvested cells were fixed with paraformaldehyde 
and stained with crystal violet (Sigma-Aldrich, St Louis, 
MO, USA), and 10 pictures were taken with an Olympus 
BX51 microscope (Olympus, Tokyo, Japan). The length 
of the scratch in each picture was determined using NIS-
Elements software from more than 10 measurements taken 
from each picture.
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Statistical analysis
Demographic, clinical and pathological data were 
summarised as frequencies (and percentages) and means 
or medians (and ranges) ± standard error of the mean, as 
appropriate. All statistical analyses were carried out using 
IBM SPSS Statistics v20. The optimal cut-off values 
identifying the methylated or unmethylated status of each 
CpG were estimated using ROC curve analysis. Across 
several cut-off points, Youden’s index was chosen as the 
best cut-off value by considering maximum sensitivity 
and specificity. The optimal cut-off values predicting OS 
and PFS were estimated as previously described [34]. 
Methylation levels in tumour, adjacent-to-tumour and 
non-neoplastic tissues were compared using the Kruskal-
Wallis test. Methylation in tumours and their adjacent 
counterparts was compared by a paired t-test. Differences 
in immunohistochemical expression were analysed with 
the Mann-Whitney and Wilcoxon tests. Correlation 
between methylation and expression in BC cell lines was 
assessed by Spearman’s correlation coefficient: U-87 
MG cells were excluded from this analysis. The effects 
of CHL1 silencing on cell proliferation, migration and 
invasion were compared using two-tailed unpaired t-tests 
at different times (0, 24, 48, 72, 96, 120 h). Finally, 
Kaplan-Meier plots and log-rank tests were used to 
examine the association of CHL1 hypermethylation with 
PFS and OS. A multivariate Cox regression model was 
fitted to test the independent contribution of each variable 
to patient outcome. Hazard ratios and 95% confidence 
intervals were used to estimate the effect of each variable 
on the outcome. Association between clinical variables 
was tested with the χ2 test.
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